Cambridge Nutritional Sciences (FRA:RVKA) 3-Year EBITDA Growth Rate: 65.10% (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cambridge Nutritional Sciences 3-Year EBITDA Growth Rate?

Cambridge Nutritional Sciences FRA:RVKA 3-Year EBITDA Growth Rate is 65.10% as of Sep. 2025. The stock has 3 warning signs investors should review. Among 691 Medical Devices & Instruments companies, Cambridge Nutritional Sciences ranks better than 92.91% on this metric.

Cambridge Nutritional Sciences's EBITDA per Share for the six months ended in Sep. 2025 was €0.00.

During the past 12 months, Cambridge Nutritional Sciences's average EBITDA Per Share Growth Rate was 350.00% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 65.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cambridge Nutritional Sciences was 65.10% per year. The lowest was -45.00% per year. And the median was 0.00% per year.

Cambridge Nutritional Sciences  (FRA:RVKA) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Cambridge Nutritional Sciences 3-Year EBITDA Growth Rate Related Terms

FRA:RVKA vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison

For the Medical Instruments & Supplies subindustry, Cambridge Nutritional Sciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cambridge Nutritional Sciences 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cambridge Nutritional Sciences's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Cambridge Nutritional Sciences's 3-Year EBITDA Growth Rate falls into.


Cambridge Nutritional Sciences 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 65.10% mean?
Cambridge Nutritional Sciences (FRA:RVKA) has a 3-Year EBITDA Growth Rate of 65.10% as of Sep. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cambridge Nutritional Sciences and its competitors. According to the industry distribution chart, Cambridge Nutritional Sciences ranks #49 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 7.1%.
Is Cambridge Nutritional Sciences' 3-Year EBITDA Growth Rate too high?
Cambridge Nutritional Sciences' current 3-Year EBITDA Growth Rate is 65.10%. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.30. Cambridge Nutritional Sciences' value of 65.10% is 684.3% above this industry median. Based on the distribution chart, Cambridge Nutritional Sciences ranks #49 out of 691 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Cambridge Nutritional Sciences' 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Cambridge Nutritional Sciences ranks #49 out of 691 companies for 3-Year EBITDA Growth Rate. This places Cambridge Nutritional Sciences in the top 7% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.30. Cambridge Nutritional Sciences' value of 65.10% is 684.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.30, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cambridge Nutritional Sciences's current 3-Year EBITDA Growth Rate of 65.10% is 684.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cambridge Nutritional Sciences and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambridge Nutritional Sciences's current 3-Year EBITDA Growth Rate is 65.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Nutritional Sciences stock overvalued right now?
Based on GuruFocus' analysis, Cambridge Nutritional Sciences (FRA:RVKA) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 27.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 65.10% and 684.3% above the Medical Devices & Instruments industry median of 8.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cambridge Nutritional Sciences (FRA:RVKA), the current 3-Year EBITDA Growth Rate is 65.10% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambridge Nutritional Sciences Business Description

Other Exchanges CNSL:UK
Address One Fleet Place, London, GBR, EC4M 7WS
Cambridge Nutritional Sciences PLC is a medical diagnostics company specializing in the development, manufacture, and distribution of food sensitivity test kits. Its product portfolio includes tests designed to detect immune reactions to various foods, helping healthcare professionals and patients identify dietary and lifestyle changes to improve long-term health and wellbeing. The company operates in the United Kingdom and serves the customer base across various countries through laboratories and healthcare providers. It generates revenue by selling diagnostic kits and providing clinical analysis services centered on food sensitivity and gut health. The group has two reportable segments: Health and Nutrition; and Corporate. The Health and Nutrition segment generates majority revenue.